These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21892317)

  • 1. A Single Institution's Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma.
    Mayer T; Lacy J; Baehring J
    Clin Med Oncol; 2008; 2():455-9. PubMed ID: 21892317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
    Lee YP; Jung HA; Lee MS; Choi JW; Kong DS; Seol HJ; Nam DH; Lee JI; Lee SH
    J Neurooncol; 2022 Feb; 156(3):541-549. PubMed ID: 35094201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.
    Mesti T; Moltara ME; Boc M; Rebersek M; Ocvirk J
    Radiol Oncol; 2015 Mar; 49(1):80-5. PubMed ID: 25810706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
    Lu G; Zhu P; Rao M; Linendoll N; Buja LM; Bhattacharjee MB; Brown RE; Ballester LY; Tian X; Pilichowska M; Wu JK; Hergenroeder GW; Glass WF; Chen L; Zhang R; Pillai AK; Hunter RL; Zhu JJ
    J Neurooncol; 2022 Oct; 160(1):221-231. PubMed ID: 36203027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
    Demirci U; Tufan G; Aktas B; Balakan O; Alacacioglu A; Dane F; Engin H; Kaplan MA; Gunaydin Y; Ozdemir NY; Tugba Unek I; Karaca H; Akman T; Sonmez OU; Coskun U; Harputluoglu H; Sevinc A; Tonyali O; Buyukberber S; Benekli M
    J Cancer Res Clin Oncol; 2013 May; 139(5):829-35. PubMed ID: 23400732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis.
    Dong J; Meng X; Li S; Chen Q; Shi L; Jiang C; Cai J
    World Neurosurg; 2019 Oct; 130():e236-e243. PubMed ID: 31203059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Vredenburgh JJ; Desjardins A; Herndon JE; Dowell JM; Reardon DA; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Wagner M; Bigner DD; Friedman AH; Friedman HS
    Clin Cancer Res; 2007 Feb; 13(4):1253-9. PubMed ID: 17317837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
    Reardon DA; Desjardins A; Peters KB; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Coan A; Threatt S; Friedman AH; Friedman HS
    Cancer; 2011 Dec; 117(23):5351-8. PubMed ID: 21590689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S; Chi SN; Young Poussaint T; Onar-Thomas A; Gilbertson RJ; Vajapeyam S; Friedman HS; Packer RJ; Rood BN; Boyett JM; Kun LE
    J Clin Oncol; 2010 Jun; 28(18):3069-75. PubMed ID: 20479404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
    Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
    Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
    Gil MJ; de Las Peñas R; Reynés G; Balañá C; Peréz-Segura P; García-Velasco A; Mesia C; Gallego O; Fernández-Chacón C; Martínez-García M; Herrero A; Andrés R; Benavides M; Quintanar T; Pérez-Martin X
    Anticancer Drugs; 2012 Jul; 23(6):659-65. PubMed ID: 22634799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
    Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
    J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
    Quant EC; Norden AD; Drappatz J; Muzikansky A; Doherty L; Lafrankie D; Ciampa A; Kesari S; Wen PY
    Neuro Oncol; 2009 Oct; 11(5):550-5. PubMed ID: 19332770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
    Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.
    Thompson EM; Dosa E; Kraemer DF; Neuwelt EA
    Neurosurgery; 2010 Jul; 67(1):87-93. PubMed ID: 20559095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
    Xu T; Chen J; Lu Y; Wolff JE
    BMC Cancer; 2010 Jun; 10():252. PubMed ID: 20525214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in recurrent high-grade pediatric gliomas.
    Narayana A; Kunnakkat S; Chacko-Mathew J; Gardner S; Karajannis M; Raza S; Wisoff J; Weiner H; Harter D; Allen J
    Neuro Oncol; 2010 Sep; 12(9):985-90. PubMed ID: 20363768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.